5//SEC Filing
Link David Charles 5
Accession 0001493152-22-004626
CIK 0001310527other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 6:11 AM ET
Size
11.4 KB
Accession
0001493152-22-004626
Insider Transaction Report
Form 5
Link David Charles
Director
Transactions
- Other
Series E-1 Preferred Stock
2021-12-06−850→ 0 total - Award
Options to buy common
2021-08-24+55,000→ 55,000 totalExercise: $0.36Exp: 2031-08-23→ Common Stock (55,000 underlying) - Other
Common Stock
2021-12-06+2,883,943→ 2,883,943 total - Award
Series E-1 Preferred Shares
2021-02-15+850→ 0 totalExercise: $0.00→ Common Stock (850,000 underlying)
Footnotes (3)
- [F1]Pursuant to reclassification exempt under Rule 16b-7, each share of Series E-1 Preferred Stock was reclassified into and exchanged for shares of Common Stock of the Issuer under the terms of Exchange Agreement and Plan of Reorganization as filed with the SEC.
- [F2]The option vests semi-annually in two equal installments beginning on 02/24/2022.
- [F3]Series E-1 Preferred Stock was convertible at any time at the discretion of the holder at a ratio of 1000 shares of Common Stock per Series E-1 Preferred Stock.
Documents
Issuer
QSAM Biosciences, Inc.
CIK 0001310527
Entity typeother
Related Parties
1- filerCIK 0001889464
Filing Metadata
- Form type
- 5
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 6:11 AM ET
- Size
- 11.4 KB